8-K: VolitionRx Secures Waiver for Market Cap Covenant Breach

VolitionRx Limited has entered into a waiver agreement with Lind Global Asset Management XII LLC following a breach of its market capitalization covenant.

Summary

• VolitionRx failed to maintain the minimum market capitalization required under its senior secured convertible promissory notes.
• The company entered into a waiver agreement with Lind Global Asset Management XII LLC on May 21, 2026.
• Lind has waived its rights to accelerate debt repayment or foreclose on collateral due to this specific covenant breach.
• The breach triggered an additional payment obligation equal to 10% of the outstanding principal amount of the notes.
• The waiver allows for the conversion of outstanding principal into common stock at a discounted rate based on recent volume-weighted average prices (VWAP).

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative development, as covenant breaches signal financial instability and the resulting penalty and potential dilution negatively impact shareholder value.

Positives

• Avoided immediate default, acceleration of debt, and potential foreclosure on collateral.
• Maintained a working relationship with the lender, Lind Global Asset Management, to resolve the covenant issue.

Negatives

• Breach of financial covenants indicates underlying financial stress or market valuation challenges.
• The breach triggered a 10% penalty on the outstanding principal amount of the notes, increasing the total debt burden.
• Potential for future dilution of shareholder equity due to the conversion terms of the notes.

Risks

• Continued inability to meet market capitalization requirements could lead to further financial strain.
• Conversion of debt into equity at a discount (90% of the three lowest VWAPs) may exert downward pressure on the share price.
• The 4.99% beneficial ownership cap on conversions limits the speed of debt reduction but keeps the dilution risk persistent.

Future Outlook

The company continues to operate under the terms of the amended notes, with the added flexibility of the waiver, while facing potential equity dilution if the lender chooses to convert debt into common stock.

Management Comments

• The company has secured a waiver to prevent immediate default and preserve its capital structure.

Industry Context

StockSavvy.ai notes that covenant breaches are increasingly common in the biotech sector as companies struggle with depressed market valuations and limited access to traditional capital markets, forcing reliance on convertible debt instruments.

Comparison to Industry Standards

• The use of convertible notes with market capitalization covenants is a standard but high-risk financing strategy for small-cap biotech firms.
• The 10% penalty for covenant breaches is consistent with aggressive private credit terms often seen in distressed or high-growth, cash-burning companies.

Stakeholder Impact

• Shareholders face potential dilution from debt-to-equity conversions.
• Creditors have secured a penalty payment, improving their position relative to the company's assets.

Next Steps

• File the full text of the waiver as an exhibit to the Form 10-Q by August 14, 2026.

Key Dates

Recommendation

The breach of financial covenants and the resulting penalty, combined with the potential for significant equity dilution, suggest a high-risk profile that warrants caution for investors.

Keywords

VolitionRx, VNRX, Convertible Notes, Covenant Breach, Debt Waiver, Lind Global Asset Management, Market Capitalization